Adipose-Derived Stem Cells From Both Visceral and Subcutaneous Fat Deposits Significantly Improve Contractile Function of Infarcted Rat Hearts
Adipose-Derived Stem Cells From Both Visceral and Subcutaneous Fat Deposits Significantly Improve Contractile Function of Infarcted Rat Hearts
复制标题
来自内脏和皮下脂肪沉积的脂肪干细胞显着改善梗塞大鼠心脏的收缩功能
DOI：
10.3727/096368914x685780
复制
发表时间：
2015-01-01
影响因子：
3.3
通讯作者：
Tian, Ganghong
中科院分区：
文献类型：
--
作者：
Chi, Chao;Wang, Fei;Tian, Ganghong
来自皮下和内脏脂肪组织的脂肪干细胞(ASCs)已经被单独研究。还没有研究比较他们在治疗心力衰竭方面的能力。这项研究旨在评估这两种来源的ASCs是否可以长期改善梗塞心脏的心功能。取大鼠皮下和内脏脂肪组织分离ASCs。对皮下ASCs(S-ASCs)和内脏ASCs(V-ASCs)的形态、产量、增殖、表面标志、分化和细胞因子的分泌进行了分析。采用冠脉结扎法建立大鼠心肌梗死模型。结扎后7d，将S-ASCs(n=22)、V-ASCs(n=22)和Dulbecco‘s改良Eagle培养液(n=20)分别注入梗死灶边缘。然后用核磁共振监测心功能，最长达6个月。然后取出心脏进行组织学评估。每克内脏脂肪的V-ASCs产量显著高于每克皮下脂肪的S-ASCs。另一方面，与V-ASCs相比，S-ASCs具有更高的增殖率和集落形成单位。此外，在细胞/DMEM移植后4周和6个月，无论是S ASCs还是V-ASCs组的心肌梗死患者的左心室射血分数均显著高于DMEM组。此外，S-ASC和V-ASC处理的心肌梗死面积均显著小于DMEM处理的心脏。恢复6个月后，MRI显示植入的ASCs。尽管在细胞产量、增殖和集落形成能力方面存在差异，但S-ASCs和V-ASCs都能长期改善心肌梗死患者的心脏收缩功能。我们得出结论，皮下脂肪组织和内脏脂肪组织是心力衰竭细胞治疗的同样有效的细胞来源。
Adipose-derived stem cells (ASCs) from subcutaneous and visceral adipose tissues have been studied individually. No studies have compared their abilities in treatment of heart failure. This study was designed to evaluate whether ASCs from the two sources could provide a long-term improvement of cardiac function in infarcted hearts. Rat subcutaneous and visceral adipose tissues were excised for isolation of ASCs. Morphology, yield, proliferation, surface markers, differentiation, and cytokine secretion of the subcutaneous ASCs (S-ASCs) and visceral ASCs (V-ASCs) were analyzed. Then a rat model of myocardial infarction (MI) was established by a coronary occlusion. Seven days after occlusion, S-ASCs (n=22), V-ASCs (n=22), and Dulbecco's modified Eagle medium (DMEM, n=20) were injected into the infarct rim, respectively. Cardiac function was then monitored with MRI for up to 6 months. The hearts were then removed for histological assessments. The yield of V-ASCs per gram of the visceral adipose depot was significantly greater than that of S-ASCs in 1 g of the subcutaneous adipose depot. On the other hand, the S-ASCs showed a greater proliferation rate and colony-forming unit relative to the V-ASCs. In addition, the infarcted hearts treated with either S-ASCs or V-ASCs showed a significantly greater left ventricular ejection fraction (LVEF) than those treated with DMEM at 4 weeks and 6 months following the cell/DMEM transplantation. Moreover, the infarct sizes of both S-ASC- and V-ASC-treated hearts were significantly smaller than that in the DMEM-treated hearts. MRI showed the implanted ASCs at the end of 6 months of recovery. Despite the differences in cell yield, proliferation, and colony formation capacity, both S-ASCs and V-ASCs provide a long-lasting improvement of cardiac contractile function in infarcted hearts. We conclude that the subcutaneous and visceral adipose tissues are equally effective cell sources for cell therapy of heart failure.